Impact of drug classes and treatment availability on the rate of antiretroviral treatment change in the TREAT Asia HIV Observational Database (TAHOD)

AIDS Research and Therapy

Volumn 4, Issue , 2007, Pages

  Srasuebkul, Preeyaporn ^a   Calmy, Alexandra ^b,c   Zhou, Jialun ^a   Kumarasamy, Nagalingeswaran ^d   Law, Matthew ^a   Lim, Poh Lian ^e  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^e TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; ASIA; COMBINATION CHEMOTHERAPY; DATA BASE; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG ERUPTION; DRUG EXPOSURE; DRUG SUBSTITUTION; DRUG USE; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTIC ACIDOSIS; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NEUROPATHY; PERIPHERAL NEUROPATHY; PRESCRIPTION; PRIORITY JOURNAL; SOCIOECONOMICS; TREAT ASIA HIV OBSERVATIONAL DATABASE; TREATMENT DURATION;

EID: 35748940019     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-4-18     Document Type: Article

References (19)

1. Joint United Nation Programme on HIV/AIDS AIDS epidemic update: Special report on HIV/AIDS: December 2006. 2006
2. World Health Organisation The 3 by 5 Initiative http://wwwwhoint/3by5/ support/updates/en/indexhtml 2006
3. World Health Organisation Antiretroviral Therapy (ART) http://wwwwhoint/ hiv/topics/arv/en/ 2007
4. Calmy A Pinoges L Szumilin E Zachariah R Ford N Ferradini L Generic fixed-dose combination antiretroviral treatment in resource-poor settings: Multicentric observational cohort Aids 2006, 20(8):1163-1169 10.1097/01.aids.0000226957.79847.d6 16691068
5. Ivers LC Kendrick D Doucette K Efficacy of antiretroviral therapy programs in resource-poor settings: A meta-analysis of the published literature Clin Infect Dis 2005, 41(2):217-224 10.1086/431199 15983918
6. Zhou J Kumarasamy N Ditangco R Kamarulzaman A Lee CK Li PC Paton NI Phanuphak P Pujari S Vibhagool A Wong WW Zhang F Chuah J Frost KR Cooper DA Law MG The TREAT Asia HIV Observational Database: Baseline and retrospective data J Acquir Immune Defic Syndr 2005, 38(2):174-179 10.1097/01.qai.0000145351.96815.d5 15671802
7. Sungkanuparph S Manosuthi W Kiertiburanakul S Piyavong B Chumpathat N Chantratita W Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails Clin Infect Dis 2007, 44(3):447-452 10.1086/510745 17205457
8. Chen RY Westfall AO Mugavero MJ Cloud GA Raper JL Chatham AG Acosta EP Taylor KH Carter J Saag MS Duration of highly active antiretroviral therapy regimens Clin Infect Dis 2003, 37(5):714-722 10.1086/377271 12942406
9. The Australian HIV Observational Database Rates of combination antiretroviral treatment change in Australia, 1997-2000 HIV Med 2002, 3(1):28-36 10.1046/j.1464-2662.2001.00094.x 12059948
10. Kumarasamy N Vallabhaneni S Cecelia AJ Yepthomi T Balakrishnan P Saghayam S Flanigan TP Carpenter CC Solomon S Mayer KH Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India J Acquir Immune Defic Syndr 2006, 41(1):53-58 10.1097/01.qai.0000188123.15493.43 16340473
11. Zhou J Paton NI Ditangco R Chen YMA Kamarulzaman A Kumarasamy N Lee CKC Li PCK Merati TP Phanuphak P Pujari S Vibhagool A Zhang F Chuah J Frost KR Cooper DA Law MG Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database HIV Med 2007, 8:816 10.1111/ j.1468-1293.2007.00417.x 17305926
12. Joint United Nation Programme on HIV/AIDS 2006 Report on the global AIDS epidemic 2006
13. Zhou J Kumarasamy N Predicting short-term disease progression among HIV-infected patients in Asia and the Pacific region: Preliminary results from the TREAT Asia HIV Observational Database (TAHOD) HIV Med 2005, 6(3):216-223 10.1111/j.1468-1293.2005.00292.x 15876289
14. The World Bank Group Country Classification 2006 http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/ 0,,contentMDK:20420458~menuPK:64133156~pagePK:64133150~piPK: 64133175~theSitePK:239419,00.html
15. Coviello V Boggess M Cumulative incidence est. in the presence of competing risks Stata Journal 2004, 4(2):164-182
16. Lunn M McNeil D Applying Cox regression to competing risks Biometrics 1995, 51(2):524-532 10.2307/2532940 7662841
17. StataCorp Stata Statistical Software:RElease 8.2 2003, 2:6-38 http://www.stata.com
18. Palella FJ Jr Chmiel JS Moorman AC Holmberg SD Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients Aids 2002, 16(12):1617-1626 10.1097/ 00002030-200208160-00007 12172083
19. Huffam SE Srasuebkul P Zhou J Calmy A Saphonn V Kaldor JM Ditangco R Prior antiretroviral therapy experience protects against zidovudine-related anaemia HIV Medicine 2007, 8(7):465-471 10.1111/ j.1468-1293.2007.00498.x 17760739